Herbert Kuster
Overview
Explore the profile of Herbert Kuster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hesselman M, Zeeb M, Rusert P, Pasin C, Mamrosh J, Kariuki S, et al.
Cell Host Microbe
. 2025 Feb;
33(2):279-293.e6.
PMID: 39909038
Identifying HIV-1 envelope (Env) traits associated with neutralization cross-reactivity is crucial for vaccine design. Variable loops 1 and 2 (V1V2), positioned at the Env trimer apex, are key regions linked...
2.
Jorimann L, Tschumi J, Zeeb M, Leemann C, Schenkel C, Neumann K, et al.
J Infect Dis
. 2023 Jul;
228(7):907-918.
PMID: 37498738
Human immunodeficiency virus type 1 (HIV-1) infection is treated with antiretroviral therapy (ART), usually consisting of 2-3 different drugs, referred to as combination ART (cART). Our recent randomized clinical trial...
3.
West E, Zeeb M, Grube C, Kuster H, Wanner K, Scheier T, et al.
Clin Infect Dis
. 2023 Jun;
77(7):1012-1020.
PMID: 37338148
Background: Starting combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection results in a smaller HIV-1 latent reservoir, reduced immune activation, and less viral diversity compared...
4.
Rindler A, Kusejko K, Kuster H, Neumann K, Leemann C, Zeeb M, et al.
J Infect Dis
. 2022 Mar;
226(6):1057-1068.
PMID: 35299248
Background: HIV-1 replication capacity (RC) of transmitted/founder viruses may influence the further course of HIV-1 infection. Methods: RCs of 355 whole-genome primary HIV-1 isolates derived from samples acquired during acute...
5.
Seifert D, Joos B, Braun D, Oberle C, Schenkel C, Kuster H, et al.
Viruses
. 2022 Feb;
14(2).
PMID: 35215999
Little is known about whether and how variation in the HIV-1 genome affects its transmissibility. Assessing which genomic features of HIV-1 are under positive or negative selection during transmission is...
6.
Moldt B, Parvangada A, Martin R, Pace C, Balakrishnan M, Thomsen N, et al.
J Acquir Immune Defic Syndr
. 2021 Aug;
88(1):61-69.
PMID: 34397744
Background: HIV envelope (env) diversity represents a significant challenge for the use of broadly neutralizing antibodies (bNAbs) in HIV treatment and cure studies. Screening for viral sensitivity to bNAbs to...
7.
Rindler A, Kuster H, Neumann K, Leemann C, Braun D, Metzner K, et al.
Viruses
. 2021 Apr;
13(3).
PMID: 33806576
HIV-1 replication capacity is an important characteristic to understand the replication competence of single variants or virus populations. It can further aid in the understanding of HIV-1 pathogenicity, disease progression,...
8.
Kok Y, Vongrad V, Chaudron S, Shilaih M, Leemann C, Neumann K, et al.
JCI Insight
. 2021 Mar;
6(9).
PMID: 33784259
HIV-1 is capable of integrating its genome into that of its host cell. We examined the influence of the activation state of CD4+ T cells, the effect of antiretroviral therapy...
9.
Liechti T, Kadelka C, Braun D, Kuster H, Boni J, Robbiani M, et al.
J Exp Med
. 2019 Jun;
216(9):2071-2090.
PMID: 31221742
Perturbations in B cells are a hallmark of HIV-1 infection. This is signified by increased numbers of exhausted CD21 memory B cells, driven by continuous antigen-specific and bystander activation. Using...
10.
Braun D, Turk T, Tschumi F, Grube C, Hampel B, Depmeier C, et al.
Clin Infect Dis
. 2019 Jan;
69(9):1489-1497.
PMID: 30601950
Background: Patients who start combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection show a smaller HIV-1 latent reservoir, less immune activation, and less viral diversity...